AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17907111 — intervention group
Group type: EXPERIMENTAL
Intervention: tesaglitazar 0.5 mg
Number of subjects: 392
Study 17907111 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 392
Study 16254580 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake assessment and biochemical measures of vitamin status
Number of subjects: 387
Study 16254580 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of plasma vitamin A and serum zinc
Number of subjects: 387
Study 11929492 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone (400 microg)
Number of subjects: 91
Study 11929492 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5 or 10 mg)
Number of subjects: 91
Study 11929492 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (24 microg)
Number of subjects: 91
Study 11929492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 10422937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.5 MAC)
Number of subjects: 20
Study 10422937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.0 MAC)
Number of subjects: 20
Study 10422937 — intervention group
Group type: COMPARATOR
Intervention: Propofol (control group)
Number of subjects: 20
Study 7498593 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirage bond/Silux
Number of subjects: 81
Study 7498593 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenure/Opalux
Number of subjects: 81
Study 7498593 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripton/Opalux
Number of subjects: 81
Study 7498593 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond 2/Silux
Number of subjects: 81
Study 2572181 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levocabastine applied twice daily
Number of subjects: 37
Study 2572181 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate applied four times a day
Number of subjects: 37
Study 1086728 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz live, further attenuated measles virus vaccine at full dose (0.5 ml)
Number of subjects: 967
Study 1086728 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz live, further attenuated measles virus vaccine at reduced doses (40%, 60%, or 80%)
Number of subjects: 967
Study 1086728 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz live, further attenuated measles virus vaccine at reduced volume below 0.5 ml
Number of subjects: 967
Study 1086728 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz live, further attenuated measles virus vaccine in children below 12 months of age
Number of subjects: 967
Study 31226790 — intervention group
Group type: EXPERIMENTAL
Intervention: IER+MED
Number of subjects: 60
Study 31226790 — intervention group
Group type: COMPARATOR
Intervention: DASH
Number of subjects: 60
Study 28376103 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 80
Study 28376103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 25788230 — intervention group
Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CTCA)
Number of subjects: 4146
Study 25788230 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 4146
Study 24261687 — intervention group
Group type: EXPERIMENTAL
Intervention: MetSizeR methodology for sample size estimation
Number of subjects: 0
Study 21985174 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline imaging after completion of 5-7 months of anticoagulant therapy
Number of subjects: 121
Study 21985174 — intervention group
Group type: COMPARATOR
Intervention: No baseline imaging after completion of 5-7 months of anticoagulant therapy
Number of subjects: 121
Study 20415155 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of strength test results
Number of subjects: 32
Study 20415155 — intervention group
Group type: COMPARATOR
Intervention: No knowledge of strength test results
Number of subjects: 32
Study 16481815 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonabsorbable packing (NAP) in the middle meatus for 5 days
Number of subjects: 61
Study 16481815 — intervention group
Group type: COMPARATOR
Intervention: Saline irrigations postoperatively (Control)
Number of subjects: 61
Study 15630988 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemo-radiotherapy in patients with resectable tumors
Number of subjects: 0
Study 15630988 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 15630988 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation
Number of subjects: 0
Study 15630988 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatments with newer chemotherapy agents and optimal radiotherapy protocols
Number of subjects: 0
Study 15630988 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative treatment strategies
Number of subjects: 0
Study 10652925 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast‐enhanced whole‐abdomen axial images
Number of subjects: 32
Study 9160851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing cigarettes (0.1 mg per puff)
Number of subjects: 12
Study 9160851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (0.5 mg nicotine per spray)
Number of subjects: 12
Study 9160851 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapor inhaler (estimated 0.013 mg nicotine per inhalation)
Number of subjects: 12
Study 9160851 — intervention group
Group type: COMPARATOR
Intervention: Control (0 puffs, sprays, or inhalations)
Number of subjects: 12
Study 8226172 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation and simultaneous daily cisplatin
Number of subjects: 0
Study 8226172 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin containing combination regimens with thoracic radiation
Number of subjects: 0
Study 8226172 — intervention group
Group type: COMPARATOR
Intervention: Thoracic radiation therapy with or without single agent cisplatin
Number of subjects: 0
Study 8226172 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation and concurrent cisplatin containing combination therapies
Number of subjects: 0
Study 8226172 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation therapy and surgery
Number of subjects: 0
Study 3780826 — intervention group
Group type: EXPERIMENTAL
Intervention: SUR2647 combination (2 g paracetamol X 2 on the day of operation, 1 g paracetamol X 2 on the following two days)
Number of subjects: 30
Study 3780826 — intervention group
Group type: EXPERIMENTAL
Intervention: SUR2647 combination
Number of subjects: 30
Study 3780826 — intervention group
Group type: COMPARATOR
Intervention: Placebo caplets
Number of subjects: 30
Study 29383893 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaoshen Kaiyu acupuncture plus standard treatment and psychological intervention
Number of subjects: 94
Study 29383893 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment plus psychological intervention (control group)
Number of subjects: 94
Study 27132819 — intervention group
Group type: EXPERIMENTAL
Intervention: MFGM containing beverage consumed for six weeks
Number of subjects: 38
Study 24879445 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment-inspired intervention
Number of subjects: 46
Study 24879445 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 22700826 — intervention group
Group type: EXPERIMENTAL
Intervention: CMS nonpayment policy for hospital-acquired CAUTI
Number of subjects: 2362742
Study 22700826 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone antimicrobial use
Number of subjects: 2362742
Study 20089562 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin and cyclophosphamide (EC)
Number of subjects: 240
Study 20089562 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin and docetaxel (ED)
Number of subjects: 240
Study 17943623 — intervention group
Group type: EXPERIMENTAL
Intervention: Irremovable total‐contact casts (TCC)
Number of subjects: 43
Study 17943623 — intervention group
Group type: COMPARATOR
Intervention: Custom‐made temporary footwear (CTF)
Number of subjects: 43
Study 15853099 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitestrips (over-the-counter technique; one cycle=30 minutes)
Number of subjects: 39
Study 15853099 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence PF 10% (at-home bleaching technique; one cycle=8 hours)
Number of subjects: 39
Study 15853099 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence Xtra Boost (in-office bleaching technique; one cycle=15 minutes)
Number of subjects: 39
Study 15853099 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 39
Study 12356153 — intervention group
Group type: EXPERIMENTAL
Intervention: CLOSED-RCT
Number of subjects: 48
Study 12356153 — intervention group
Group type: COMPARATOR
Intervention: OPEN-RCT
Number of subjects: 48
Study 12356153 — intervention group
Group type: EXPERIMENTAL
Intervention: CLOSED-nonRCT
Number of subjects: 48
Study 12356153 — intervention group
Group type: COMPARATOR
Intervention: OPEN-nonRCT
Number of subjects: 48
Study 10224721 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide bleaching system 1
Number of subjects: 24
Study 10224721 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide bleaching system 2
Number of subjects: 24
Study 10224721 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide bleaching system 3
Number of subjects: 24
Study 10224721 — intervention group
Group type: COMPARATOR
Intervention: Comparison among the three bleaching systems
Number of subjects: 24
Study 8544547 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine (up to 120 mg daily)
Number of subjects: 46
Study 8544547 — intervention group
Group type: COMPARATOR
Intervention: Benztropine (active placebo, up to 1 mg twice daily)
Number of subjects: 46
Study 1860151 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-based oral rehydration therapy (ORT)
Number of subjects: 68345
Study 1860151 — intervention group
Group type: COMPARATOR
Intervention: Sugar-based oral rehydration therapy (ORT)
Number of subjects: 68345
Study 6351594 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 40
Study 6351594 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 40
Study 30576555 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (60 mg/d)
Number of subjects: 54
Study 30576555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (200 mg/d)
Number of subjects: 54
Study 30576555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 27068885 — intervention group
Group type: EXPERIMENTAL
Intervention: NasoPore packing
Number of subjects: 50
Study 27068885 — intervention group
Group type: COMPARATOR
Intervention: Non-resorbable traditional impregnated gauze packing
Number of subjects: 50
Study 26304476 — intervention group
Group type: EXPERIMENTAL
Intervention: Commitment-based behaviour change techniques (reminders, implementation intentions, public commitment) combined with information
Number of subjects: 710
Study 26304476 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping planning with reminders and information (in phase 2)
Number of subjects: 710
Study 26304476 — intervention group
Group type: COMPARATOR
Intervention: Information-only control group
Number of subjects: 710
Study 25112302 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 200
Study 25112302 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous saline solution)
Number of subjects: 200
Study 21208417 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram
Number of subjects: 2016
Study 21208417 — intervention group
Group type: EXPERIMENTAL
Intervention: sertraline
Number of subjects: 2016
Study 21208417 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine
Number of subjects: 2016
Study 21208417 — intervention group
Group type: COMPARATOR
Intervention: healthy controls
Number of subjects: 2016
Study 19659492 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS training for chest pain or dyspnoea
Number of subjects: 146
Study 17365749 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing plus brief office intervention
Number of subjects: 196
Study 17365749 — intervention group
Group type: COMPARATOR
Intervention: Brief office intervention
Number of subjects: 196
Study 14715336 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated patients with metabolic syndrome in 4S
Number of subjects: 2
Study 14715336 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated patients with metabolic syndrome in AFCAPS/TexCAPS
Number of subjects: 2
Study 14715336 — intervention group
Group type: EXPERIMENTAL
Intervention: Low high-density lipoprotein levels
Number of subjects: 2
Study 14715336 — intervention group
Group type: EXPERIMENTAL
Intervention: High triglycerides in 4S
Number of subjects: 2
Study 14715336 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated blood pressure and obesity in AFCAPS/TexCAPS
Number of subjects: 2
Study 14715336 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with metabolic syndrome
Number of subjects: 2
Study 11285552 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postoperative radiation therapy (RT)
Number of subjects: 0
Study 11285552 — intervention group
Group type: COMPARATOR
Intervention: Delayed radiation therapy (RT)
Number of subjects: 0
Study 11285552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiation therapy (approximately 45-50 Gray (Gy))
Number of subjects: 0
Study 11285552 — intervention group
Group type: COMPARATOR
Intervention: High-dose radiation therapy (approximately 60-65 Gy)
Number of subjects: 0
Study 9336558 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking/running group
Number of subjects: 31
Study 9336558 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling group
Number of subjects: 31
Study 9336558 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group
Number of subjects: 31
Study 8179231 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of terfenadine twice daily for 1 week
Number of subjects: 19
Study 8179231 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 1 week
Number of subjects: 19
Study 2885946 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodilution (graded venesection 250‐1000 ml during the first 2 days and dextran 40 infusions 500 ml daily for 5 days)
Number of subjects: 373
Study 2885946 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodilution
Number of subjects: 373
Study 2885946 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 373
Study 30324496 — intervention group
Group type: EXPERIMENTAL
Intervention: Snapcare app (App group) in addition to a written prescription
Number of subjects: 93
Study 30324496 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Conventional group) with a written prescription
Number of subjects: 93
Study 26896734 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin plus albumin
Number of subjects: 196
Study 26896734 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus albumin
Number of subjects: 196
Study 25437716 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical intralesional vasopressin injection
Number of subjects: 40
Study 25437716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23289262 — intervention group
Group type: EXPERIMENTAL
Intervention: First trimester of pregnancy
Number of subjects: 130
Study 23289262 — intervention group
Group type: EXPERIMENTAL
Intervention: Second trimester of pregnancy
Number of subjects: 130
Study 23289262 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sexual satisfaction
Number of subjects: 130
Study 23289262 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of sexual contacts
Number of subjects: 130
Study 20334708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate seed oil (PSO) 400 mg twice daily
Number of subjects: 51
Study 20334708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 18773990 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (E-Alone)
Number of subjects: 24532
Study 18773990 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (E+P)
Number of subjects: 24532
Study 15904514 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid Vi polysaccharide vaccine
Number of subjects: 118588
Study 11921698 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal Replacement Therapy (HRT)
Number of subjects: 70
Study 11921698 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 9895090 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% enflurane with 80% N2O
Number of subjects: 14
Study 9895090 — intervention group
Group type: COMPARATOR
Intervention: 0.2% enflurane without 80% N2O
Number of subjects: 14
Study 7573074 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomly assigned intensity of exposure (0.1-40 fibers/ml)
Number of subjects: 200
Study 7573074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative exposure
Number of subjects: 200
Study 2099961 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravenous and oral Pentoxifylline
Number of subjects: 16
Study 2099961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7007058 — intervention group
Group type: EXPERIMENTAL
Intervention: Methenamine hippurate (MH), 1 g three times daily
Number of subjects: 0
Study 7007058 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 1 g three times daily
Number of subjects: 0
Study 30957284 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-miRNA signature (miR130b, miR-18a, miR-223)
Number of subjects: 0
Study 30957284 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-miRNA signature
Number of subjects: 0
Study 30957284 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms integrating three-miRNA signature and clinicopathological risk factors
Number of subjects: 0
Study 28066879 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly dosing
Number of subjects: 0
Study 26175533 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized site performance feedback intervention at 73 hospitals (n=33,886 patients)
Number of subjects: 71829
Study 26175533 — intervention group
Group type: COMPARATOR
Intervention: Control group at 74 hospitals (n=37,943 patients)
Number of subjects: 71829
Study 26175533 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual achievement measures and quality measures
Number of subjects: 71829
Study 23190780 — intervention group
Group type: EXPERIMENTAL
Intervention: PncCRM vaccine
Number of subjects: 2497
Study 23190780 — intervention group
Group type: EXPERIMENTAL
Intervention: PncOMPC vaccine
Number of subjects: 2497
Study 23190780 — intervention group
Group type: COMPARATOR
Intervention: Control group (hepatitis B vaccine)
Number of subjects: 2497
Study 21104834 — intervention group
Group type: EXPERIMENTAL
Intervention: Fsoy (aglycone-rich fermented soybeans)
Number of subjects: 11
Study 20017681 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal FM systems used during the school day for 6 weeks
Number of subjects: 46
Study 20017681 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FM systems)
Number of subjects: 46
Study 16061916 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity presentation format
Number of subjects: 183
Study 16061916 — intervention group
Group type: EXPERIMENTAL
Intervention: Likelihood ratio presentation format
Number of subjects: 183
Study 16061916 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical presentation format
Number of subjects: 183
Study 16061916 — intervention group
Group type: COMPARATOR
Intervention: Sensitivity and specificity vs. likelihood ratio
Number of subjects: 183
Study 12476605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9924864 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Early Intervention Program (EIP) with 4 prenatal classes and approximately 17 home visits by specially trained public health nurses.
Number of subjects: 121
Study 9924864 — intervention group
Group type: COMPARATOR
Intervention: Traditional Public Health Nursing (TPHN) care with three home visits.
Number of subjects: 121
Study 8950498 — intervention group
Group type: EXPERIMENTAL
Intervention: Inogatran (low molecular weight thrombin inhibitor)
Number of subjects: 37
Study 2031078 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha 2b-interferon alone (6 weeks of placebo syrup followed by 16 weeks of recombinant alpha 2b-interferon, 5 x 10(6) u/m2 subcutaneously thrice weekly)
Number of subjects: 90
Study 2031078 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha 2b-interferon with steroid priming (6 weeks of syrup prednisone followed by 16 weeks of recombinant alpha 2b-interferon)
Number of subjects: 90
Study 2031078 — intervention group
Group type: COMPARATOR
Intervention: Control group (syrup vitamin B complex)
Number of subjects: 90
Study 2031078 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 7171405 — intervention group
Group type: EXPERIMENTAL
Intervention: Remler M2000
Number of subjects: 58
Study 7171405 — intervention group
Group type: COMPARATOR
Intervention: Hawksley sphygmomanometer
Number of subjects: 58
Study 7171405 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphygmolog
Number of subjects: 58
Study 7171405 — intervention group
Group type: EXPERIMENTAL
Intervention: Remler
Number of subjects: 58
Study 31551223 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of Zushima tablet and western medicine
Number of subjects: 170
Study 31551223 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 170
Study 28384523 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal school-based intervention targeting resilience protective factors
Number of subjects: 3115
Study 28384523 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3115
Study 25554995 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 138
Study 25554995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 25554995 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 138
Study 22546664 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of personal concerns
Number of subjects: 34